Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Brand Image Still Hinders Acceptance of GE Drugs: PJ, So-net M3 Survey
January 19, 2004
- FY 2004 Business Plan Approved: JPMA General Assembly
January 19, 2004
- BUSINESS NEWS IN BRIEF
January 19, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
January 19, 2004
- AstraZeneca Integrates R&D in Japan into AZ Global Development
January 19, 2004
- WEBSITE NEWS
January 19, 2004
- 1 in 3 Glaucoma Patients Has Poor Compliance: Patient Body Survey
January 19, 2004
- Expecting Better Allocation of Medical Fees in FY2004: Health Minister
January 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
January 19, 2004
- Dr Sakaguchi Appeals for Steps to Prevent Medical Accidents
January 19, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 19, 2004
- Korosho to Establish System to More Quickly Approve New Indications: PFSB DG
January 19, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 19, 2004
- Korosho to Approve Additional Indications for More Anti-cancer Drugs
January 19, 2004
- OTC NEWS IN BRIEF
January 19, 2004
- Chuikyo to Resume Discussions on 80% Rule for 1st Generics
January 19, 2004
- Meet the Leaders (29)
January 19, 2004
- Korosho Rejects Requests for Expanded Participation in Structural Reform Zones
January 19, 2004
- Takeda's Blopress Aims for 40% Share in ARB Market
January 19, 2004
- Births Down 3rd Year in a Row, Hit Historic Low in 2003: Vital Statistics
January 19, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…